SIMD is the medical abbreviation for substance-induced mood disorder: depression, mania or a mixed mood state caused by the direct effects of alcohol, a drug or a medication, during intoxication, withdrawal or exposure. DSM-5-TR splits it into substance/medication-induced depressive disorder and substance/medication-induced bipolar and related disorder.

The term comes from DSM-IV, which grouped these presentations as substance-induced mood disorder. The current manual, DSM-5-TR, moves them into their parent chapters, so the depressive form now sits beside major depressive disorder and the manic form beside bipolar disorder, but SIMD psychiatry shorthand survived on charts, in residency teaching and in the research literature. The idea is simple. Some chemicals can produce a full mood syndrome on their own, and when they do, the mood problem is a consequence of the substance rather than a separate illness. The diagnosis matters because the treatment differs: an induced depression often lifts as the substance clears, while an independent depression needs its own treatment whatever happens with the drinking. Telling the two apart is a clinical judgment, and it is also the first question worth asking about depression that does not look like depression in someone who still performs well at work.

Five substance patterns behind induced mood symptoms

What the evidence means for treatment

Who is affected by the diagnosis

An SIMD diagnosis decides what gets treated first, so it shapes more than one person's plan. These are the people whose decisions depend on getting it right.

Substance-induced mood disorder gets missed because the symptoms look identical to major depression and the substance history is rarely volunteered. High-functioning professionals often describe the low mood in detail and mention the drinking, the stimulant or the new prescription last, if at all.

An SIMD diagnosis rests on timing. DSM-5-TR counts a mood episode as substance-induced when it developed during or soon after use, withdrawal or a medication, the substance can produce it, and it is not better explained by an independent disorder. Symptoms that predate use or persist after about a month of abstinence point to independent depression.

The clinician reconstructs the sequence. Did the mood symptoms exist before the substance use began? Did they appear or spike with a new substance, a heavier pattern or a new prescription? Have there been stretches of abstinence, and what did mood do during them? Reviews of the evidence recommend looking for depression outside periods of drinking or withdrawal, and using reports from family members when possible.

Abstinence is the clearest test. McHugh and Weiss, writing in the NIAAA's journal Alcohol Research: Current Reviews, describe alcohol-induced depression as a syndrome that occurs during and shortly after intoxication or withdrawal and remits after 3 to 4 weeks of abstinence; if symptoms persist past about 4 weeks, an independent depressive disorder can be diagnosed with more confidence. The first label is provisional. Follow-up studies reviewed by Tolliver and Anton found that many people first diagnosed with SIMD were reclassified with major depression over time, so an induced diagnosis is a reason to keep watching mood, not to stop.

Assessment is where CEREVITY's nationwide network of independent licensed clinicians starts: a careful history before any plan, and coordination with the reader's own physician or psychiatrist on medication and medically supervised withdrawal. You can read how treatment gets planned before anyone books a standing weekly slot before committing to anything.

The executive whose wind-down stopped working

The patternTwo drinks to switch off became four. Sleep fragments, mornings are flat and irritable, and the low mood now feels like the main problem. An antidepressant has not helped, and the drinking has never been discussed in detail.

What we addressTreatment starts with an honest timeline and a planned period of reduced or no drinking, with medical input where withdrawal is a risk, then measures what mood does as the alcohol clears. The stress the drinking was managing often turns out to be burnout, and clinical care for burnout that never shows in results treats it directly.

The professional whose mood tracks a prescription

The patternA stimulant for focus, a steroid course or a new sleep medication, and within weeks the mood has changed: elevated and wired, or low and flat. Nobody has lined up the dates.

What we addressTherapy builds the timeline and the reader takes it to the prescriber, who decides on any medication change. Where the exhaustion behind the stimulant use is the real story, clinicians work on that too, often as burnout treatment for executives.

SIMD treatment usually works in sequence: reduce or stop the substance with medical support where needed, re-assess mood as the chemistry clears, then treat any depression that remains. CEREVITY clinicians use cognitive behavioral therapy and motivational interviewing, which a meta-analysis found effective for depression and alcohol use together.

Modality 01

Structured assessment

A substance and mood timeline built to DSM-5-TR criteria, with periods of use, withdrawal and abstinence mapped against mood.

Modality 02

Motivational interviewing

Meets ambivalence about changing use honestly, without lectures, which matters when the substance is still doing a job.

Modality 03

Cognitive behavioral therapy (CBT)

Targets the thoughts and routines that make the substance feel necessary, and rebuilds the coping it was hired to perform.

Modality 04

Behavioral activation

Restores rewarding, values-based activity, which both depression and heavy use erode, and tracks mood day by day.

Modality 05

Coordinated medical care

Medication decisions and supervised withdrawal stay with the reader's physician or psychiatrist; therapy runs alongside them.

Private-pay, nationwide, and built around discretion

At CEREVITY, our online individual therapy sessions are structured as a direct investment in your mental agility and overall well-being. The investment includes:

View rates & investment options

The cost of a substance-driven mood problem going unaddressed

Consider what is at stake when a substance-driven mood problem goes unaddressed:

Treatment aimed at the wrong target

When an induced depression is treated as an independent one, a failed antidepressant can read as treatment resistance while the driver stays untouched. When an independent depression is dismissed as induced, needed treatment waits. Private-pay care means no diagnosis on a claim record while the question is still open. View our current rates here.

Session formats that fit assessment

Sessions run by secure telehealth across all 50 states. Ongoing work usually uses 50-minute therapy sessions. A full substance and mood history often fits better in 90-minute therapy sessions, and some clients use 3-hour intensive sessions to complete it at once. When depression remains after the substance clears, intensive therapy for depression is available.

Population surveys and clinics tell different stories. In the national NESARC survey, fewer than 1% of people meeting criteria for a mood disorder were classified as having SIMD, as Tolliver and Anton report in Dialogues in Clinical Neuroscience, while McHugh and Weiss note a study in which more than 25% of patients in alcohol treatment had experienced a substance-induced depressive episode in their lifetime. The label also shifts over time: in NESARC follow-up, 95% of people first classified with SIMD who had a later depressive episode were reclassified as having major depression.

► What the research reports

42%

of men entering alcohol treatment had clinically significant depression at admission.

Brown and Schuckit, Journal of Studies on Alcohol, 1988

6%

of the same men were still clinically depressed after four weeks of abstinence.

Brown and Schuckit, Journal of Studies on Alcohol, 1988

37.2%

of US adults used a prescription drug that lists depression as a potential adverse effect.

Qato, Ozenberger and Olfson, JAMA, 2018

Medication is part of the picture. Qato and colleagues, in JAMA, found that 37.2% of US adults used a prescription medication that lists depression as a potential adverse effect, and depression was more common in people taking three or more of them. On treatment, a meta-analysis of 12 studies with 1,721 patients found that combined cognitive behavioral therapy and motivational interviewing produced small but clinically significant reductions in both drinking and depressive symptoms compared with usual care.